Source comparison
PT-141 vs Flibanserin vs Testosterone: Mechanism and Outcome Comparison
All three are used for hypoactive sexual desire, but they work through entirely different systems. Flibanserin (Addyi) is a daily oral serotonin receptor modulator. It downregulates 5-HT2A receptors (which inhibit dopamine and norepinephrine) while upregulatin
This comparison does not assign a generated winner or score.
- All three are used for hypoactive sexual desire, but they work through entirely different systems. Flibanserin (Addyi) is a daily oral serotonin receptor modulator. It downregulates 5-HT2A receptors (which inhibit dopamine and norepinephrine) while upregulating 5-HT1A (which disinhibits these same neurotransmitters). The effect is chronic: it takes 4–8 weeks of daily dosing to see measurable improvement in desire scores. PT-141 is acute: subcutaneous injection 45 minutes before anticipated sexual activity produces rapid-onset arousal that peaks within 2–3 hours.
- Testosterone therapy addresses androgen deficiency. Low total or free testosterone levels measured via serum assay. It's prescribed when desire loss correlates with documented hypogonadism, often postmenopausal or post-oophorectomy. PT-141 is prescribed when desire is low despite normal hormone levels. The diagnosis is functional HSDD, not endocrine insufficiency. We've seen researchers attempt to stack PT-141 with testosterone replacement; the data doesn't support additive benefit. If androgen levels are optimised and desire remains suppressed, the deficit is receptor-level, not hormonal.
- The adverse event profiles diverge sharply. Flibanserin's black-box warning involves severe hypotension and syncope when combined with alcohol. A contraindication that limited real-world uptake. PT-141's most common side effects are nausea (40% of patients in RECONNECT), flushing (20%), and transient blood pressure increases averaging 3–4 mmHg systolic. These resolve within 12 hours and don't accumulate with repeat dosing. Testosterone carries risks of virilisation, lipid changes, and cardiovascular events in women. Risks absent with PT-141 because it doesn't alter hormone levels at all.
- Our experience reviewing published trials and investigator-initiated studies: PT-141 performs best in patients with primary HSDD (desire was never robust) rather than secondary HSDD (desire declined after a clear precipitating event). Flibanserin shows marginally better outcomes in secondary cases where serotonin dysregulation from SSRIs or life stressors is the proximate cause. Testosterone works when the blood test confirms the diagnosis. Choosing the wrong agent for the wrong mechanism produces disappointing outcomes. We've reviewed datasets where investigators used PT-141 in populations with obvious androgen deficiency and reported 'non-response.'